 NEWARK, Calif., Nov. 16, 2020 GLOBE NEWSWIRE -- CymaBay Therapeutics, Inc. NASDAQ: CBAY, a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced an oral late-breaking presentation of the positive results from the ENHANCE phase 3 study evaluating seladelpar for primary biliary cholangitis PBC. These data were presented online today during the late-breaking session at The Liver Meeting of the American Association for the Study of Liver Diseases AASLD. 